BioCentury
ARTICLE | Clinical News

CPC-111 fructose-1 data

October 20, 1997 7:00 AM UTC

CYPR announced positive results from its double-blind Phase II trial of CPC-111 to reduce pain associated with sickle cell anemia crisis. A total of 47 patients were given single intravenous infusions of placebo or 50, 100, or 250 mg/kg CPC-111 when a sickling crisis occurred. All three dose groups produced similar reductions in pain compared to placebo, with the 50 and 100 mg dose groups showing statistically significant effects.

The company noted that even the lowest dose was above the threshold necessary to saturate the metabolic pathway, which could account for the lack of a dose response. No safety issues were noted at any dose. ...